Ceribell Inc (CBLL) Stock Forecast & Price Target

CeriBell is viewed favorably because it has already outperformed revenue expectations, beaten Street sales forecasts, and raised guidance every quarter since its IPO, while growing its total addressable market from $2B to more than $3.5B through pediatric, neonate, and delirium approvals. Its core appeal is a differentiated bedside EEG platform that can be deployed in minutes by nonspecialists, supported by strong clinical validation, reimbursement coverage, gross margin of 92.3% in Q2, and an expanding installed base of 712 hospitals. The bull case is reinforced by a long runway with less than 4% core-market penetration, a sales force still maturing toward maximum productivity, and additional upside from a 2026 delirium launch, Q4 expansion, and next-gen hardware and algorithm enhancements.

CeriBell is facing a challenging fundamental backdrop because delirium is often hypoactive or unresponsive, while current CAM-ICU and ICDSC testing is intermittent, subjective, and vulnerable to nurse turnover, limiting the near-term adoption thesis for point-of-care EEG. Although the company is described as having rapid growth, a market-leading position, and a best-in-class margin profile, the cited risks around competition, regulatory decisions, delays in new product launches, and weaker reimbursement could pressure execution and slow the realization of that runway. Further downside stems from macro and supply-chain exposure, as tariffs on China imports could reduce gross margins, force sourcing shifts to Vietnam, and increase uncertainty around profitability and product economics.